Northwestern University Feinberg School of Medicine
Department of Medicine
Skip to main content

Division Chief's Message

Clyde W. Yancy

For three consecutive years, we have ranked among the top 10 cardiology and heart surgery programs in the nation.”

Clyde W. Yancy, MD, MSc, MACC, FAHA, MACP, FHFSA
Chief, Division of Cardiology
Vice Dean, Diversity & Inclusion
Magerstadt Professor of Medicine
Professor of Medical Social Science,
Associate Director, Bluhm Cardiovascular Institute
Northwestern Memorial Hospital

As the Chief of Cardiology at Northwestern University Feinberg School of Medicine, I am delighted to welcome you to this website.

Our division is driven by excellence. For three consecutive years, we have ranked among the top 10 Cardiology and Heart Surgery programs in the nation (U.S. News & World Report). As a top-tier Division of Cardiology, we insist on delivering expert clinical care through Northwestern Memorial Hospital and our affiliated care sites. We strive to extend the fund of knowledge in cardiovascular medicine by our active research portfolio. We embrace the responsibility to educate current and future practitioners of cardiovascular medicine, and we ensure that our continuing medical education programs are exceptional.

We are committed to the study of cardiovascular disease beginning with a better understanding of risk, careful understanding of disease pathophysiology, critical insight into the efficacy of known treatment options and a deep exploration of novel therapeutic interventions. Our division is uniquely known for our leadership in prevention, quality of care strategies for patients with cardiovascular disease and our leadership in the generation of contemporary clinical practice guidelines and performance measures. Through our alignments with our Northwestern Medicine partners — the Feinberg Cardiovascular and Renal Research Institute and the Department of Preventive Medicine — we are able to participate and take a leading role in translational discovery and population health.

Within our division is leading-edge talent who can expertly employ all contemporary cardiovascular interventions indicated for hypertension, acute coronary syndromes, atrial and ventricular arrhythmias, valvular heart disease and advanced heart failure. Most importantly, we take a thoughtful patient-centric approach to deploy the correct therapy at the correct time for each patient. Our legacy is prevention, and we stridently work to take a proactive approach that prevents the onset of disease or the progression of established disease for all patients who seek care with us.

We are excited about our leadership roles in transcutaneous aortic valve replacement, mitral valve repair, advanced therapies for advanced heart failure, all modalities of care for atrial fibrillation and acute coronary syndromes and acute heart failure. Both of these common conditions are treated in an expert manner at Northwestern. We lead the nation with the lowest 30-day mortality after admission for heart failure, and we are second in the nation for acute myocardial infarction mortality.

Our investigators are actively exploring new dimensions of cardiovascular clinical and translational science. We have an alignment with the National Heart, Lung, and Blood Institute’s Heart Failure Clinical Research Network, and we are leading large multi-institutional clinical trials in heart failure, valvular heart disease and atrial fibrillation. We have introduced the benefit of big data analytics (phenomapping) to better identify novel disease phenotypes that may lead to better therapies, and we have a well-established cardiovascular genetics program with expertise in the assessment especially of all forms of cardiomyopathies and the cardiovascular consequences of muscular dystrophy. We have also launched a T-1 translational science center to begin discovery with first-in-man compounds, and we are among the first centers to pursue percutaneous replacement of the tricuspid valve.

Additionally, we are also developing new risk models to determine freedom from heart failure, and we have identified novel applications of machine learning and business theory to better address and lower rehospitalization rates after episodes of acute heart failure. To that end, we are exploring innovative wearable technologies that will streamline the assessment of cardiovascular risk.

Our basic investigators are exploring biological models that determine the origin of atrial fibrillation, fibrosis and hypertrophy of the heart as modulated by dietary inorganic phosphates and iron metabolism in the heart and cellular regeneration. We are among the top three recipients nationally of research support from the American Heart Association and now hold three strategically focused research network grants. Our investigators are on the leading edge of aging theory and are beginning to explore small molecule development that may reduce the burden of chronic diseases that are largely driven by age-related changes. All of these active areas of active investigation are potentially poised to change the practice of cardiovascular medicine.

As a division, we are most enthused about the quality of our Cardiovascular Fellowship Training programs. We have more than 30 cardiology fellows pursuing training in general cardiology and subspecialty training in electrophysiology, heart failure, imaging and interventional cardiology. We hold two T32 training grants: one in prevention and one in molecular cardiology. We encourage additional expertise through graduate degree programs in clinical investigation, bioinformatics and public health.

We believe the amalgamation of our experience and excellence as practitioners, educators, investigators and citizens at this institution in the remarkable city of Chicago provides an unparalleled environment in which we can thrive as leaders of cardiovascular medicine in the United States.

Back to top